Contrasting with concerns about pancreatic and thyroid cancers, emerging evidence suggests that GLP-1 RAs may inhibit the growth of several types of cancer, including ovarian, breast, cervical, prostate, and pancreatic cancers [29-31]
This transformation comes at a crucial time as the obesity treatment landscape undergoes rapid evolution with analysts projecting the GLP-1 market to exceed $100 billion by 2030.1 AI is fundamentally changing how we conduct and optimize clinical trials for GLP-1 therapies
When you have an experience that makes you feel good whether its eating certain foods, socializing, drinking alcohol, or using nicotine the brains reward center is activated, causing the release of dopamine, a neurotransmitter
JZP-458 was well tolerated in phase I clinical trials
doi: 10.1158/0008-5472.Can-09-2747 78 ChenXIliopoulosDZhangQTangQGreenblattMBHatziapostolouMet al